NCT00324363 - Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin | Biotech Hunter

Enrollment

466

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

exenatide

subcutaneous injection, 5mcg or 10mcg, twice a day for 16 weeks

DRUG

Placebo

subcutaneous injection twice daily in volumes equal to exenatide

Trial Locations (14)

Research Site, Beijing

Research Site, Guangzhou

Research Site, Nanjing

Research Site, Shanghai

Research Site, Sichuan

Research Site, Chennai

Research Site, Mumbai

Research Site, Pune

Research Site, Seoul

Research Site, Sungnam City

Research Site, Chiayi City

Research Site, Taichung

Research Site, Tainan City

Research Site, Taipei